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differently. When analysts report the results of study, both total and incremental 
budget impact should be presented for each year of the time horizon. Sensitivity 
analysis was emphasized in order to identify the uncertainty within the analytic 
framework. The guidelines suggested that the discounting is unnecessary and 
encourage model validation except those of Poland. CONCLUSIONS: This review 
discovered that Canada, Ireland, Poland, and ISPOR BIA guidelines were 
consistent in basic analytic framework, but details were depended on payer 
perspective and regional specificity. This study is expected to help to develop 
Korean BIA guidelines.  
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OBJECTIVES: The European Medicines Agency (EMA) and the United States Food 
and Drug Administration (FDA) have different regulatory systems for the review 
and approval of new drugs. This study reviewed and compared the 
characteristics of priority review new pharmaceuticals (i.e. new molecular 
entities -NME- and new therapeutic biologics -BLA-) approved by EMA and the 
FDA in the period 2006-2011. METHODS: Data were extracted from the FDA and 
EMA websites. Dates of application and approval and orphan status information 
were extracted from the FDA approval letters and the EMA public assessment 
reports. Descriptive statistics were used to compare the approval processes and 
characteristics of both systems; t-test was used to assess differences in average 
review time. Significant level was set at 0.05. RESULTS: A total of 47 drugs (34 
NME and 13 BLA) were approved by both regulatory agencies in the study period. 
BLAs were submitted to the FDA 22±166 days earlier (median=10 days) and 
approved by the FDA 211±145 days earlier (median=168 days) than the EMEA. 
NMEs were submitted to the EMA 229±832 days earlier (median=33) and 
approved by the EMA 97±884 days earlier (median=173 days) than the FDA. The 
average review time was statistically significantly lower (p<0.001) for the FDA 
258±200 days (median=184 days) than for EMA 406±96 (median=407 days). The 
number of products with orphan designation at the time of the first approval 
was higher in the FDA (n=20) than in the EMA (n=15). EMA granted orphan 
designation at the time of approval to two products that did not have orphan 
designation in the US. CONCLUSIONS: There are significant differences in the 
time elapsed between the filing and the approval of priority review products in 
the US and EU. Orphan designation also varied between the two regulatory 
systems. Harmonization of the regulatory systems could facilitate timely 
approval of essential pharmaceuticals.  
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OBJECTIVES: In January 2008, the Food and Drug Administration (FDA) 
communicated concerns and later in May 2009, issued a warning about an 
increased risk of suicidality related to all antiepileptic drugs (AEDs). The purpose 
of this study is to evaluate the association between an FDA suicidality warning 
and AED use among Oklahoma Medicaid enrollees diagnosed with epilepsy 
and/or psychiatric disorder(s). METHODS: A longitudinal interrupted design was 
conducted to study Oklahoma Medicaid claims data from January 2006 through 
December 2009. A total of 13,126 individuals met the study criteria: diagnosis 
with epilepsy and/or psychiatric disorder(s) and filling of at least one AED 
prescription. A segmented logistic regression model compared the level and 
trend in the log odds of AED use among three time periods: a baseline period of 
25 months (Jan. 2006 - Jan. 2008) before the FDA warning; the 16 months (Feb. 
2008-May 2009) during the FDA warning; and the 7 months (June 2009-Dec. 2009) 
after the FDA warning. Generalized estimation equations (GEE) were used to 
estimate trends in AED utilization while adjusting for several covariates. 
RESULTS: There was a statistical increase in the trend, expressed as a monthly 
change in log odds of AED use, before the FDA warning period (p<0.0001). 
However, this trend decreased by 34% (99% CI: 10.2% to 57.6%, p=0.0002) during 
the FDA warning period when compared to the baseline trend. This decrease in 
trend did not remain significant after the FDA warning period (p=0.2957). 
Compared with the baseline level of AED utilization before the FDA warning 
period, the log odds of AED utilization level also decreased by 22% (99% CI: 1.9% 
42.2%, p=0.0048) after the FDA warning period. CONCLUSIONS: The FDA 
suicidality warning was associated with a reduction in overall AED use among 
this population.  
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OBJECTIVES: Since December 2010, online computerized prospective DUR(pDUR) 
has been implemented in Korea. pDUR involves the review of each prescription 
before the medication is dispensed to the individual patient. The pDUR is 
performed electronically by Health Insurance Review & Assessment Service 
(HIRA), which is a Korean governmental agency, and then HIRA provides medical 
institutions and pharmacies with information that can be helpful to them in 
preventing potential drug problems such as drug/drug interactions or ingredient 
duplication. The aim of this study was to assess the impact of the Korean pDUR 
implementation on the rate of drug-drug interactions (DDIs) using claims data of 
HIRA. METHODS: A before-after comparison of the prevalence of DDIs was 
conducted, using HIRA administrative claims data from medical institutions 
from January 2010 to December 2011. In addition, a paired t-test was applied to 
examine the difference between the pre- and post-pDUR. The analysis unit was 
the prescription issued and main outcome measures were the rates of DDIs 
within- (control group) or between- physician encounters. RESULTS: The mean 
DDIs rates (pre-test and post-test) within patient visits were 0.29‰ and 0.22‰, 
respectively. The mean rates of DDIs between visits were 0.94‰ (before) and 
0.80‰ (after). As a result of the t-test, we found that DDIs rate between 
encounters decreased significantly (t=3.04, p=0.0026) after the implementation of 
pDUR, whereas there is no significant reduction within encounters (t=1.15, 
p=0.2518). With respect to the prevalence of DDIs between drug groups, the most 
dramatic reduction was occurred between HMG CoA reductase inhibitors and 
anti-fungal agents. CONCLUSIONS: It seems effective that giving a direct 
feedback to prescribers by a prospective DUR. Further research is needed to 
assess the impact of DUR to final outcomes such as hospitalization.  
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OBJECTIVES: US Food and Drug Administration (FDA) approval does not 
necessarily equate with coverage by the Centers for Medicare and Medicaid 
Services (CMS) or private payers for a device or a drug. The FDA is charged with 
determining the safety and efficacy of medical products. In contrast, payers are 
primarily concerned with whether medical products are reasonable and 
necessary. As health care costs continue to rise, manufacturers face increasing 
pressures to justify product prices and provide rationale to payers to support 
favorable funding decisions. Our objective was to review coverage decisions for 
devices and reasons for noncoverage to determine whether payers are expecting 
more pharmaceutical-like evidence. METHODS: We reviewed Washington State 
Health Technology Assessment (HTA) decisions for therapeutics from 2007 
through 2012. Reasons for noncoverage were classified as lack of clinical efficacy 
or other. RESULTS: We identified 22 therapeutic HTA reviews, of which 11 
included some level of noncoverage determination for the product or procedure. 
The reason for noncoverage was stated as a perceived lack of clinical efficacy 
evidence. For example, a 2008 decision against implantable infusion pumps for 
the treatment of chronic noncancer pain was based partly on the fact that “[t]he 
only kind of evidence about whether implantable infusion pumps are effective 
for patients with chronic noncancer pain comes from uncontrolled case series.” 
Such statements demonstrate the disparity between FDA approval of devices 
and payer expectations for efficacy evidence to support coverage decisions. 
Payer evidence requirements for medical devices continue to move closer to 
those historically associated with pharmaceuticals. CONCLUSIONS: No roadmap 
exists for determination of reasonable and necessary levels of evidence for 
device-coverage decisions. FDA and payer evidence requirements are not 
aligned. Moving forward, evidence-generation efforts for devices will, in most 
cases, have to exceed FDA requirements in order for payer evidence needs to be 
met.  
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OBJECTIVES: To examine how five global pharmaceutical companies are 
currently developing comparative effectiveness research (CER) and relative 
effectiveness (RE) evidence. METHODS: We followed two parallel steps. First, a 
targeted literature review was performed. Second, a semi-structured interview 
program was conducted with 19 senior key informants (KI) across the five 
companies. After analyzing the interview results using systematic content 
review, we merged these findings with the literature review to extrapolate the 
final study results. RESULTS: We found a clear recognition of the growing 
importance of CER/RE within the industry, although the KIs differed regarding 
whether this was a disruptive change or simply an extension of traditional 
outcomes research efforts. Most viewed the payer/HTA community as the 
biggest driver of CER/RE evidence needs, rather than patients or clinicians. 
Nearly all KIs stated that their organizations already incorporate CER/RE criteria 
into their current drug development paradigm (CDDP), but differed in the timing 
(phase of development), degree of investment, whether CER/RE considerations 
influenced go/no-go decisions and type of product. Barriers to adaptation of the 
CDDP included historic prioritization of regulatory approval; concerns about 
increased study costs and complexity; heterogeneity of stakeholder evidence 
requirements; and difficulty integrating across departments. Facilitators of 
change included increasing CER/RE expectations of payers/HTA bodies and 
having senior management serve as an internal CER/RE champion. Most 
interviewees believed that CER/RE would play a greater role in drug development 
by 2020, particularly driven by payer/HTA demands for evidence of value. 
CONCLUSIONS: Our interviews revealed that there has been a spectrum  
of response to the perceived need for CER/RE data that involves altering the 
CDDP in a variety of important ways to include primarily the information needs 
of payers and HTA bodies. These changes to the CDDP are projected to grow  
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by the year 2020, primarily because of external demands and internal 
investments.  
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OBJECTIVES: Health technology assessment bodies are increasingly reviewing 
the clinical and economic evidence on various surgical procedures. Such reviews 
typically use a hierarchy of evidence, with randomized controlled trials (RCTs) 
designated Level I evidence and case-control and case-series studies designated 
Levels III and IV. The objective of this study was to explore the evidence 
available to determine the value of a well-established surgical procedure. 
METHODS: A structured search of PubMed was conducted on rotator cuff surgery 
using Medical Subject Heading search terms. Internet searches identified 
evidence-based guidelines for this condition. RESULTS: Two RCTs evaluating the 
efficacy of arthroscopic repair of rotator cuff tears concluded that arthroscopic 
repair was superior to the alternatives studied. Ten systematic reviews 
examining studies of surgical technique modifications for rotator cuff surgery 
were identified. All 10 reviews reported that, despite limitations, there was 
enough evidence to identify surgical techniques that resulted in improved 
clinical outcomes. Most of the systematic reviews found Level III or Level IV 
evidence for recommending one type of surgery over another. In 2010, the 
American Academy of Orthopaedic Surgeons (AAOS) published evidence-based 
guidelines to improve treatment for 25 different rotator cuff problems; 74 studies 
were deemed of sufficient quality for use in the guidelines. However, more than 
half of the 25 recommendations (n=15) were characterized as inconclusive owing 
to the levels of evidence available for review. CONCLUSIONS: The 
pharmaceutical framework for evidence hierarchy often may not be appropriate 
for surgical procedures and devices. There are challenges to running clinical 
trials in surgical setting, making them impractical and unaffordable. Especially 
with well-established procedures, evidence review will require a balanced 
approach using the best available evidence and clinical expertise.  
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OBJECTIVES: The Affordable Care Act (ACA) has been upheld by the United 
States Supreme Court. Four principles of the ACA are driving changes in the US 
health care system, those principles are improving outcomes, quality, safety and 
containing costs. This study looks at several product outcomes guarantees to see 
if they support the cited ACA principles to benefit the health care system. 
METHODS: A review and analysis of published payer coverage policies and 
contracts entered into by product manufacturers with several US payers. 
RESULTS: Three publically available examples were analyzed and described 
herein: a) WellPoint analyzed over 55,000 claims for use of zafirlukast, 
montelukast sodium and zileuton and determined that outcomes for these 
products were better and more cost effective even when used first-line, outside 
of FDA indication; b) Cigna entered into an agreement with Merck where 
additional rebates are paid by Merck if patients who are on sitagliptin if patients 
stay on therapy and see blood sugar levels fall; c) EMD Serono and Prime 
Therapeutics have an agreement where rebates are paid if the total cost of care 
of an interferon beta 1a patient is greater than a patient on other MS drugs, or if 
adherence to the drug exceeds a specified level. CONCLUSIONS: Outcomes 
guarantees by product manufacturers are still in their infancy in the United 
States, but recent examples show that payers are looking at these agreements as 
a way to improve outcomes and control costs. The ACA may help to drive more 
outcomes guarantee agreements because they do support the key principles of 
the ACA. Drug manufacturers must clearly understand how their products will 
perform when used outside of a clinical trial in order to negotiate such 
agreements.  
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OBJECTIVES: Our aim was to gather perspectives from a diverse group of payers 
on how the rapidly evolving field of comparative effectiveness research 
(CER)/relative effectiveness (RE) will impact evidentiary standards for pricing and 
coverage decisions by 2020. METHODS: We conducted semi-structured 
interviews with 16 senior officials representing large payers, accountable care 
organizations, HTA groups, and pricing and reimbursement bodies in the US and 
Europe. An online survey was used to assess current use of CER/RE evidence and 
potential trends that might influence its use for decision making by 2020. The 
interview was designed to elicit their definitions of CER/RE and structured 
around 4 hypothetical cases resembling therapeutics expected to be more 
common and poised to create policy challenges by 2020. Topics included 
acceptance of designs (e.g., pragmatic trials) and analytic methods associated 
with CER/RE (e.g., indirect comparisons). A systematic content review was used 
to extract relevant information. RESULTS: While there was marked diversity in 
responses, there were some common themes. Respondents anticipate growing 
reliance on policy levers such as conditional reimbursement and prior 
authorization to control diffusion. Randomization will remain an essential 
component to assess comparative effectiveness. Respondents anticipate more 
aggressively using techniques like cluster randomization to conduct studies in 
their population. Case studies provided important insights into situations when 
certain types of CER evidence may be acceptable (e.g., observational data when 
differences between drugs are largely convenience). Payers would like to see but 
remain skeptical about harmonized approaches such as adaptive licensing to 
stage evidence development. CONCLUSIONS: Industry perceptions that CER will 
change payers' evidentiary requirements in the future are consistent with our 
findings. This arises both from a growing investment in analyses of their own 
data and increased reliance on policy tools to control diffusion that will drive the 
type of evidence industry will be required to produce.  
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OBJECTIVES: In the development and post-launch support of medicines, there 
are a myriad of issues in selecting comparator(s) for trials, studies, modeling 
and/or other analyses. The principles and process for the selection of 
comparators has a limited body of literature focused mainly on the randomized 
control trial design. Guidance documents exist but are not always sufficiently 
clear or consistent in their criteria. Our objective is to examine the complexities 
in making a generalizable comparator selection considering the many issues and 
questions found in the literature. METHODS: We conducted a comprehensive 
search of the published and grey literature, guidelines from regulatory, HTA, and 
professional organizations that addressed the comparator selection process as 
well as case studies and published opinion on the issue. We excluded 
publications that did not address issues, principles, and criteria for selecting 
comparators. We independently assessed this review with the final framework 
developed by team consensus. RESULTS: We propose a framework organizing 
the principles, methods and unresolved issues for the appropriate selection of a 
comparator product. It consists of: 1) foundational elements (e.g., clinical 
equipoise, ethical issues); 2) gaps in existing knowledge (e.g., systematic 
evidence reviews, is there a clear standard of care?); 3) hypotheses/questions to 
be addressed (e.g., intended purpose of the study/analysis, known characteristics 
of the investigational product); 4) study or analyses design-specific comparator 
criteria; and 5) exploration and validation of the proposed choice(s). 
CONCLUSIONS: Currently, several efforts are underway to define a clear and 
equitable process for comparator selection that is more consistent and 
acceptable to decision-makers and stakeholders. Our proposed framework could 
help support development of a more transparent and harmonized comparator 
selection process that better addresses the evidence needs of industry, 
regulators, HTA agencies and payers.  
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OBJECTIVES: To understand hospitalization costs, expenses covered by 
insurance and disease distribution among urban inpatients with basic health 
insurance (BHI) in China between 2009 and 2010, providing data evidence for the 
government further improving BHI policies and drug regulation system. 
METHODS: A nationwide, cross-sectional sampling of urban inpatients with BHI 
was conducted in mainland China. A retrospective analysis was adopted and all 
results were extrapolated to the whole country according to the population, 
economics and other factors in the inpatients’ cities. The statistics analysis 
software was SQL Server 2003. RESULTS: There were 31,460,000 cases after 
extrapolated (sample=236,366) in 2010, with an increase of 13.92% than that of 
the previous year. Second-class hospitals received more hospitalization cases 
(45.47% of the total ) in 2010 than the previous year (41.28% of the total). Average 
hospitalization cost per visit in 2010 was 8056 RMB, an increase of 5.05% from the 
previous year. Remarkably, medication expenses accounted for about 49%, which 
was approximately equal to the previous year. The expenses covered by BHI 
accounted for 67.73% for each vist, which was higher than that of the previous 
year. Cerebrovascular disease had the most hospitalization cases (9.95% of the 
total), followed by cancer, ischemic heart disease, Hypertension and chronic 
lower respiratory diseases. The total hospitalization cost of cancer (36.403 billion 
RMB) was the highest, followed by cerebrovascular disease (25.242 billion RMB) 
and ischemic heart disease (20.472 billion RMB). CONCLUSIONS: The average 
hospitalization costs per visit and total hospitalization costs all increased. And 
rational drug use should be still paid more attention since the drug costs 
percentage was steadily high. Helping inpatients select proper hospitals to see 
doctors and strengthening the administration of diseases cost highly will be 
helpful for reducing the medical costs.  
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